IRON

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presents updated data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASCO Annual Meeting in Chicago, IL. In this updated data set, treatment with DISC-0974 shows substantial reductions in hepci

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decisionBitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026 WATERTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the launch of an expanded access program (EAP) for bitopertin for eligible patient

Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemiaAdditional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT study (patient survey on life and health impact of disease), and DISC-3405 trial in progress for polycythemia veraManagement will host a corporate update conference call on Monday, June 15 at 8:00 am ET WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today a

WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 19th at 4:30 p.m. ET.Jefferies Global Healthcare Conference on Wednesday, June 3rd at 3:10 p.m. ET. Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com

10-Q - Disc Medicine, Inc. (0001816736) (Filer)

8-K - Disc Medicine, Inc. (0001816736) (Filer)

Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026Updated data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) to be shared at the American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentationProgressing ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and Phase 1b study of DISC-3405 in sickle cell disease (SCD), with data from both studies expected in Q4 2026Strong financial position ending Q1 with approximately $730 million in cash, cash equivalents, and marketable securities, providing runway into 2029 WATERTOWN, Mass., May 05, 2026 (GLOBE

DEFA14A - Disc Medicine, Inc. (0001816736) (Filer)

DEF 14A - Disc Medicine, Inc. (0001816736) (Filer)

WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis (MF) in an oral abstract session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago, IL on May 29-June 2, 2026. "Initial data from the RALLY-MF trial showed anemia response rates that are unprecedented in the hard-to-treat myelofibrosis population," said Jo

4 - Disc Medicine, Inc. (0001816736) (Issuer)

4 - Disc Medicine, Inc. (0001816736) (Issuer)

Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician demandResults of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as an N=150 stud

4 - Disc Medicine, Inc. (0001816736) (Issuer)

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

144 - Disc Medicine, Inc. (0001816736) (Subject)

4 - Disc Medicine, Inc. (0001816736) (Issuer)

8-K - Disc Medicine, Inc. (0001816736) (Filer)

S-8 - Disc Medicine, Inc. (0001816736) (Filer)

10-K - Disc Medicine, Inc. (0001816736) (Filer)

8-K - Disc Medicine, Inc. (0001816736) (Filer)

Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at the American Society of Hematology (ASH) conference demonstrating meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor therapy useProgressing ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and initiated a Phase 1b study of DISC-3405 in sickle cell disease (SCD) in Q4 2025, with data from both studi

144 - Disc Medicine, Inc. (0001816736) (Subject)

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd at 9:50 a.m. ET in Boston, MA.Leerink Global Healthcare Conference on Monday, March 9th at 3:40 p.m. ET in Miami, FL. Disc management will be participating in investor meetings during the above conferences, as well as the Jefferies Biotech on the Beach Summit on March 1

4 - Disc Medicine, Inc. (0001816736) (Issuer)